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Background
Coxsackievirus A21 (CAVATAKTM) is a bio-selected
oncolytic immunotherapy virus. Following intravenous
(i.v) administration, CAVATAK can preferentially infect
ICAM-1 expressing tumor cell, resulting in tumor cell
lysis and generate a potential systemic immune-
mediated anti-tumor response. A Phase I/II trial of i.v
delivered CAVATAK (NCT01227551) in advanced can-
cer patients displayed signs of anti-tumor activity in
some lesions. Blockade of programmed death protein-1
(PD-1) and or CTLA-4 in patients with metastatic mela-
noma, NSCLC and metastatic Bladder cancer has
resulted in substantial tumor responses via a mechanism
involving reversal of tumor induced T cell suppression.
We hypothesized that combinations of intravenous deli-
verved CAVATAK and PD-1 or CTLA-4 blockade may
enhance anti-tumor responses, potentially leading to
improved clinical activity.
Methods
Preclinical studies in C57BL mice were conducted to
assess the anti-tumor activity of CAVATAK and anti-
mouse PD-1 (mPD-1) mAb or anti-CTLA-4 (mCTLA-4)
mAb in a B16-ICAM-1 melanoma immune competent
mouse model. B16-ICAM-1 cells are murine melanoma
B16 cells stably transfected to express human ICAM-1
allowing CAVATAK binding and cell infection. CAVA-
TAK was administered i.v, while anti mPD-1 or
mCTLA-4 mAbs were delivered via the intraperitoneal
route. Following treatment of the primary cutaneous
B16-ICAM-1 tumor with 4 cycles of CAVATAK injec-
tions and 4 cycles of anti-PD-1 or anti-CTLA-4 mAbs,
mice were then re-challenged with an additional subcu-
taneous administration of B16 cells.
Results
Significant single agent anti-tumor activities against the
primary B16-ICAM-1 tumors were observed in mice
treated with either CAVATAK, anti-PD-1 or anti-
CTLA-4 mAbs relative to saline controls. Furthermore,
combinations of CAVATAK and anti-PD-1 or anti-
CTLA-4 mAbs mediated significantly greater anti-tumor
activity and offered greater survival benefits when com-
pared to use of either agent alone. Of particular interest
was the finding that combinations of CAVATAK and
anti-PD-1 or anti-CTLA-4 mAbs were able to noticeably
delay the onset of palpable tumor development follow-
ing B16 cell re-challenge when compared to all other
single agent treatment regimes.
Conclusions
The significant anti-tumor activity mediated by the
combination of CAVATAK and checkpoint inhibitor
antibodies (anti-PD-1 and anti-CTLA-4) observed in the
presented murine melanoma model supports clinical
evaluation of such an immunotherapeutic combination
treatment regime in patients with advanced melanoma.
Clinical evaluation of CAVATAK in combination with
immune checkpoint blockade in advanced melanoma
patients is currently underway.
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